Novo Nordisk A/S (LTS:0QIU) Short-Term Capital Lease Obligation : kr1,174 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S Short-Term Capital Lease Obligation?

Novo Nordisk A/S's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr1,174 Mil.

Novo Nordisk A/S's quarterly Short-Term Capital Lease Obligation stayed the same from Jun. 2023 (kr0 Mil) to Sep. 2023 (kr0 Mil) but then increased from Sep. 2023 (kr0 Mil) to Dec. 2023 (kr1,174 Mil).

Novo Nordisk A/S's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (kr822 Mil) to Dec. 2022 (kr986 Mil) and increased from Dec. 2022 (kr986 Mil) to Dec. 2023 (kr1,174 Mil).

Novo Nordisk A/S Short-Term Capital Lease Obligation Historical Data

The historical data trend for Novo Nordisk A/S's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Short-Term Capital Lease Obligation Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

815.00

775.00

822.00

986.00

1,174.00

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															986.00	-	-	-	1,174.00

Novo Nordisk A/S Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Novo Nordisk A/S Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (LTS:0QIU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines